Brokers Issue Forecasts for ITOS Q2 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Leerink Partnrs issued their Q2 2025 earnings per share estimates for iTeos Therapeutics in a note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch expects that the company will earn ($0.62) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($0.48) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.94) EPS.

A number of other equities analysts have also recently commented on the company. Raymond James set a $12.00 price target on iTeos Therapeutics in a report on Wednesday, May 14th. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. HC Wainwright cut shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. Leerink Partners restated a “market perform” rating and issued a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $13.00 price target (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, iTeos Therapeutics presently has an average rating of “Hold” and an average target price of $17.86.

iTeos Therapeutics Stock Performance

ITOS opened at $8.35 on Monday. iTeos Therapeutics has a 52-week low of $4.80 and a 52-week high of $18.30. The firm has a market cap of $319.59 million, a P/E ratio of -2.65 and a beta of 1.39. The business’s fifty day moving average is $6.65 and its 200-day moving average is $7.40.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14.

Insider Transactions at iTeos Therapeutics

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the sale, the insider now directly owns 2,108,594 shares of the company’s stock, valued at approximately $16,995,267.64. This represents a 23.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now owns 3,452,797 shares of the company’s stock, valued at approximately $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ITOS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of iTeos Therapeutics in the 4th quarter worth about $42,000. CWM LLC grew its stake in iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after purchasing an additional 6,936 shares during the period. Paloma Partners Management Co bought a new stake in iTeos Therapeutics in the first quarter worth approximately $65,000. Dynamic Technology Lab Private Ltd acquired a new position in iTeos Therapeutics in the first quarter valued at approximately $67,000. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.